Diamyd Medical AB Class B · OMXSTO:DMYD_B

Diamyd Medical AB Class B — Investor Presentation (January 2023)

46 slides from Diamyd Medical AB Class B's investor presentation, January 2023

  1. Slide 1: Precision Medicine for Autoimmune Diabetes in Pivotal Phase 3

    Precision Medicine for Autoimmune Diabetes in Pivotal Phase 3

  2. Slide 2: Disclaimer

    DISCLAIMER This Presentation (”Presentation”) has been prepared by Diamyd Medical AB (“Diamyd” or “the Company”). By accepting this Presentation, the recipient acknowledges and agree to the following: The information contained herein have been prepared to assist interested parties making their own e

  3. Slide 3: Targeting Autoimmune and Insulin Deficient Diabetes

    TARGETING AUTOIMMUNE AND INSULIN DEFICIENT DIABETES Leading clinical stage pipeline • First-in-class disease modifying therapies Diamyd® and Remygen® • Pivotal program with a precision medicine approach De-risked development program • Responder patients identified for Diamyd®, significantly increasi

  4. Slide 4: Autoimmune Diabetes

    AUTOIMMUNE DIABETES Significant unmet medical need and health economic burden Type 1 Diabetes ~ 500,000 new cases every year* 184,100 children and adolescents (0-19 years of age) and 329,000 adults are diagnosed with type 1 diabetes every year. It is more prevalent in western countries with the high

  5. Slide 5: Significant Annual Economic Burden of Type 1 Diabetes

    SIGNIFICANT ANNUAL ECONOMIC BURDEN OF TYPE 1 DIABETES Disease modifying therapies for T1D are predicted to have a multibillion-dollar economic impact in the US alone 1) Modelling the total economic value of novel T1D therapeutic concepts, January 2020, Health Advances. 5

  6. Slide 6: Leading pipeline targeting autoimmune diabetes

    Leading pipeline targeting autoimmune diabetes Sample Development Phase Product Indication Sponsor Status size Preclinical I II III Ongoing in Europe, approved Recently-diagnosed 330 (target) Diamyd DIAGNODE-3 to start in the US clinical (Stage 3) T1D Medical Topline H2 2026 Recently-diagnosed Linkö

  7. Slide 7: Diamyd®

    Diamyd® Recombinant GAD65 Formulated in Alum (rhGAD65/alum) Primary Indication Diamyd® New-onset (stage 3) Type 1 Diabetes with HLA type DR3-DQ2 Label Expansion Type 1 Diabetes prevention (stage 1 & 2), LADA Mechanism of Action Induce immunological tolerance against GAD65 Clinical Effect and Benefit

  8. Slide 8: Multibillion total addressable market for Diamyd®

    Multibillion total addressable market for Diamyd® >500 000 new cases of T1D globally every year ~ 130 000 in the US and • Estimated pricing in US in line with Europe existing drugs on the market (65k – 100k+) ~ 50 000 carry • Market for Stage 3 T1D with HLA DR3- HLA DR3-DQ2 DQ2 in US and Europe > $2

  9. Slide 9: Focus on preemptive medicine

    Focus on preemptive medicine Diamyd® is designed to prevent diabetes complications and improve glucose control by stopping the autoimmune destruction of beta cells Reduced risk of1 ● Severe hypoglycemia Illustrative decline of functional beta ● Life-threatening ketoacidosis cell mass in autoimmune d

  10. Slide 10: Significant label expansion opportunities for Diamyd®

    Significant label expansion opportunities for Diamyd® Stage 3 Stage 1&2 LADA Boosters Combinations T1D T1D

  11. Slide 11: Position Diamyd® to maximize efficacy, safety, convenience

    POSITION DIAMYD® TO MAXIMIZE EFFICACY, SAFETY, CONVENIENCE Disease modifying therapies Added value compared to standard of care Immunosuppressive Antigen-specific treatments Cell therapies technologies Effect, Benefit Antigen-specific immunotherapy with Diamyd® Artificial targets the body’s immune s

  12. Slide 12: New-onset (Stage 3) Type 1 Diabetes with HLA type DR3-DQ2

    New-onset (Stage 3) Type 1 Diabetes with HLA type DR3-DQ2 12

  13. Slide 13: Responders to Diamyd® treatment

    RESPONDERS TO DIAMYD® TREATMENT Genetic variants influence T1D is a collection GAD-specific immunotherapy is influenced by the same genetic the appearance of of distinct variants that influence autoimmunity. Individuals with GAD autoimmunity endotypes autoimmunity respond best to GAD immunotherapy S

  14. Slide 14: Crucial research advances in precision medicine for type 1 diabetes

    CRUCIAL RESEARCH ADVANCES IN PRECISION MEDICINE FOR TYPE 1 DIABETES Antigen- Antigen- reactive presenting cell T cell Significant treatment effects on: 1. Preservation of endogenous insulin production HLA is central to response 2. Improved HbA1c GAD65 3. Less glycemic variability 4. More time spent

  15. Slide 15: HLA influences effect of Diamyd®

    HLA INFLUENCES EFFECT OF DIAMYD® Significant and dose-dependent treatment effect of Diamyd® (GAD-alum) in HLA DR3-DQ2 positive individuals on preservation of own insulin production and HbA1c Meta-analysis with >600 recent-onset T1D patients 4 RCTs (Phase III EUR, Phase II SWE, Phase II US, Phase IIb

  16. Slide 16: Correlated treatment effects on C-peptide and HbA1c

    CORRELATED TREATMENT EFFECTS (CHANGE FROM BASELINE TO MONTH 15 VERSUS PLACEBO) ON C-PEPTIDE AND HBA1C 3 or 4 doses of Diamyd® vs Placebo Without HLA DR3-DQ2 With HLA DR3-DQ2 Sensitivity analyses, including adjustment for insulin dose, confirm robust effect Size of circle is corresponding to the rela

  17. Slide 17: The first ever precision medicine Phase III trial in Type 1 Diabetes

    The first ever precision medicine Phase III trial in Type 1 Diabetes • Diamyd® in individuals recently diagnosed with type 1 diabetes and positive for the HLA DR3-DQ2 haplotype • Ongoing in 8 European countries, approved to start in the US

  18. Slide 18: Results support design of pivotal Phase III trial DIAGNODE-3

    RESULTS SUPPORT DESIGN OF PIVOTAL, GLOBAL PHASE III TRIAL DIAGNODE-3 • Responder population HLA DR3-DQ2 (40-50%) with GADA, 12-28 yr, <6m T1D DR3-DQ2-pos/ • Intralympatic injections (superior to subcutaneous injections) DR4-DQ8-neg • 3 monthly injections (superior to 2 injections) DR3-DQ2-pos H2 𝛂2

  19. Slide 19: Latent Autoimmune Diabetes in Adults (LADA)

    Latent Autoimmune Diabetes in Adults (LADA)* *Also called Slowly progressing Autoimmune Diabetes (SAID) or Slowly progressing insulin- dependent diabetes mellitus (SPIDDM) 19

  20. Slide 20: Background

    Background In highly autoimmune LADA individuals: treatment that directly targets autoimmunity is needed *p< 0.007 Hals IK, Fiskvik Fleiner H, Reimers N, Astor MC, Filipsson K, Ma Z, Grill V, Björklund A. Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: Resu

  21. Slide 21: Levels vs. Baseline (%)

    Glucagon-stimulated C-peptide levels unchanged at 12 months vs Baseline (0 months) in the HLA-DR3DQ2 positive subgroup Phase 2 trial with Diamyd in up to 70 year-old LADA patients Glucagon-stimulated C-peptide * * 100 DR3DQ2 negative (n=7) Levels vs. Baseline (%) DR3DQ2 positive (n=7) 95 90 85 80 0

  22. Slide 22: Conclusions

    Conclusions • Treatment with intralymphatic GAD is well tolerated in LADA individuals – no safety concerns • GAD-induced immune responses appear compatible with those in studies with type 1 diabetes • Results on C-peptide suggest an HLA-dependent beneficial effect akin to type 1 diabetes Also see •

  23. Slide 23: Type 1 Diabetes prevention (Stage 1 & 2)

    Type 1 Diabetes prevention (Stage 1 & 2) 23

  24. Slide 24: Diamyd Medical coordinates the ASSET milieu

    DIAMYD MEDICAL COORDINATES THE ASSET MILIEU A T1D Forum to drive precision medicine, prevention and screening Contact with T1D research community Aim for a European-level Partnerships in contact network developing AI algorithms Discuss best practices for Integration of data from screening programs d

  25. Slide 25: About ASSET

    ABOUT ASSET The innovation milieu ASSET (AI for Sustainable Prevention of Autoimmunity in the Society – www.asset.healthcare) will develop and evaluate new algorithms based on AI to be able to assess the individual risk of developing Type 1 Diabetes (T1D), and the likelihood of responding to differe

  26. Slide 26: Safety and administration of Diamyd®

    Safety and administration of Diamyd® 26

  27. Slide 27: Intralymphatic administration route enhances effect of Diamyd®

    Intralymphatic administration route enhances effect of Diamyd® antigen- specific immunotherapy in Type 1 Diabetes 27 27

  28. Slide 28: More efficient uptake in lymph nodes following intralymphatic administration

    MORE EFFICIENT UPTAKE IN AND DRAINAGE TO LYMPH NODES FOLLOWING INTRALYMPHATIC COMPARED TO SUBCUTANEOUS ADMINISTRATION Lessons Learned from Allergy Immunotherapy Trials Subcutaneously (S.C.) injected large molecules including proteins do not effectively spread to the draining lymphnodes. Intranodal (

  29. Slide 29: Convenient outpatient procedure enhances value proposition

    CONVENIENT OUTPATIENT PROCEDURE ENHANCES VALUE PROPOSITION FOR DIAMYD® Potential to reach patients outside specialized clinics and avoiding costs related to hospitalization Intralymphatic Appointment Ultrasound Treated patient administration (minutes) (seconds) The procedure is performed by a radiol

  30. Slide 30: Superior safety profile

    SUPERIOR SAFETY PROFILE Patient drop-out rate in clinical trials Total patient exposure 14% Diamyd Placebo 12% 12% 10% 990 513 8% 7% 6% 4% Most commonly reported adverse events: • tenderness, injection site edema, injection site pain 2% and injection site reaction. 0.8% • no difference in the rate o

  31. Slide 31: Manufacturing and Market Exclusivity of Diamyd®

    Manufacturing and Market Exclusivity of Diamyd® 31

  32. Slide 32: Biomanufacturing – control and predictability

    • 20,000 square feet site comprising clean rooms, Biomanufacturing – laboratory facilities and office space • In-house manufacturing of recombinant GAD65 (active control and pharmaceutical ingredient in the diabetes vaccine Diamyd®) predictability • Independent of third parties • Goal to be producti

  33. Slide 33: Diamyd® (rhGAD65/alum) manufacturing

    DIAMYD® (rhGAD65/ALUM) MANUFACTURING Baculovirus expression system Upstream & process: Insect cells Clarification DP formulation Downstream Capture process: Polish Nanofiltration 33

  34. Slide 34: Diamyd® IP & market exclusivity

    DIAMYD® IP & MARKET EXCLUSIVITY Core Intellectual Property • Substance of matter in the US until 2032 • Intralymphatic administration of Diamyd® in Europe, Japan, China, Australia and Russia, additional countries pending, expiry 2035. • Intralymphatic administration of additional betacell antigens (

  35. Slide 35: Remygen®

    Modified Release GABA Primary Indication Type 1 diabetes Remygen® Label expansion LADA, Insulin-deficient type 2 diabetes Mechanism of Action Activate GABA-receptors in the pancreas Clinical Effect • Regenerate endogenous insulin production, reduce short- and long-term complications • Prevention of

  36. Slide 36: Clinical results with attractive path to market for Remygen®

    CLINICAL RESULTS WITH ATTRACTIVE PATH TO MARKET FOR REMYGEN® ▪ Ongoing clinical Phase IIa trial* ▪ ReGenerate-1 at the University of Uppsala where Remygen® (proprietary formulation of GABA) alone and in combination with low-dose alprazolam (GABA receptor modulator to enhance effect, see next slide)

  37. Slide 37: GABA induces a hormonal counter-regulatory response

    Open access Original research [rere GABA induces a hormonal counter- Diabetes =~eeee, regulatory response in subjects with & Care long-standing type 1 diabetes Daniel Espes © ,"? Hanna Liljeback,** Henrik Hill,° Andris Elksnis,° José Caballero-Corbalan,* Per-Ola Carlsson** e Dtamyb » MEDICAL

  38. Slide 38: GABA treatment improves the hormonal response to hypoglycemia

    GABA TREATMENT IMPROVES THE HORMONAL RESPONSE TO HYPOGLYCEMIA GH response to hypoglycemia Glucagon response to hypoglycemia 10 8 Growth Hormone (µg/L) Normoglycemia Normoglycemia Glucagon (pmol/L) 8 Hypoglycemia Hypoglycemia 6 * 6 * 4 4 2 2 0 0 e e e e e se se se lin os os os in do do do e d d d el

  39. Slide 39: Positive allosteric modulators enhance GABA's beta cell regenerative effects

    Positive allosteric modulators Effect of PAMs on INS-1 cell proliferation. INS-1 cells were cultured with the indicated PAM at a dose range of 10 −9 to 10−6 M and assessed for their proliferation. Data shown are the average rate of proliferation relative to that of cultures with media alone (designa

  40. Slide 40: Remygen® market exclusivity and manufacturing

    REMYGEN® MARKET EXCLUSIVITY AND MANUFACTURING Core Intellectual Property • Exclusive license from UCLA on treating diabetes and other inflammatory diseases with GABA • Formulation patent application (Remygen®). Application in national phase. • Exclusive license from UCLA on GABA in combination with

  41. Slide 41: Organization, Board, Management and Scientific Advisors

    Organization, Board, Management and Scientific Advisors 41

  42. Slide 42: Board of Directors

    Erik Nerpin Anders Essen-Möller Maria-Teresa Essen- Torbjörn Bäckström Mark A. Atkinson Karin Hehenberger Möller Born in 1961. Lawyer. Self- Born in 1941. M.Sc. Founder Born in 1970. M.Sc. in Born in 1948. MD, PhD. CEO Born in 1961. PhD. Professor of Born in 1972. M.D., Ph.D, employed with of and CE

  43. Slide 43: Management team

    Ulf Hannelius Martina Widman Anna Styrud Anton Lindqvist Chief Executive Officer Chief Operating Officer Chief Financial Officer Chief Scientific Officer Born in 1975. PhD in Molecular Biology from Karolinska Born in 1981. M.Sc. in Mechanical Engineering from the Born in 1961. B.Sc. in Business Admi

  44. Slide 44: Top worldwide experts

    TOP WORLDWIDE EXPERTS Covering the areas of clinical practice and scientific excellence in Type 1 Diabetes and LADA Prof. Johnny Ludvigsson Prof. David Leslie Prof. Åke Lernmark Prof. Daniel Kaufman Prof. Mark A. Atkinson Professor of Pediatrics. First Professor of Diabetes and Professor in Experime

  45. Slide 45: Diamyd Medical

    DIAMYD MEDICAL • Swedish clinical phase pharmaceutical company, founded 1994 • NASDAQ First North Growth Market, ticker DMYD B FINANCES • Market Cap Jan 25, 2023 ~ MSEK 1 210 • Cash Nov 30, 2022: MSEK 131 INDICATIONS • Diabetes • Autoimmunity PRODUCT CANDIDATES • Diamyd® (Phase III) • Remygen® (Phas

  46. Slide 46: Diamyd Medical

    Diamyd Medical www.diamyd.com

Diamyd Medical — Investor Presentation (January 2023) on 6ix